Skip to content

Bioalmanac

Vesugen

Lys-Glu-Asp · Vascular peptide

Preclinical

Status reviewed 18 Aug 2026

The vascular peptide of the family, described in the originating work as supporting the endothelium. One institute, four decades, no outside replication.

Storage

Freeze-dried powder
Refrigerated at 2–8 °C, protected from light.
After mixing
Refrigerated at 2–8 °C. Do not freeze once mixed.
Long-term, frozen
Unopened powder is stable at −20 °C or colder.

Reconstitution — 20 mg vial, 2000 mcg dose

On a 1 mL U-100 syringe. Check every figure against your own vial before drawing.

Water addedConcentrationVolume to drawUnitsDoses per vial
1 mL20 mg/mL0.1 mL10 units10
2 mL10 mg/mL0.2 mL20 units10
3 mL6.667 mg/mL0.3 mL30 units10
5 mL4 mg/mL0.5 mL50 units10

Dose ranges reported in sources

Descriptions of what sources report, not recommendations.

GoalRangeFrequencySource
Course described in community sources1000–2000 mcgDaily for a 10-day course, repeated a few times a yearCommunity practice

When to stop

  • Any allergic response: rash, hives, facial swelling or difficulty breathing. Seek urgent care.
  • An injection site that becomes hot, spreading or produces pus.
  • Any new or unexplained symptom you would ordinarily see a doctor about.

Not approved for human use in the United States, the European Union or the United Kingdom. Some peptides in this family are registered in Russia as supplements or medicines. Vesugen is sold elsewhere as a research chemical.

Arithmetic on values you enter. Not medical advice. Not reviewed by a clinician. · bioalmanac.com/peptides/vesugen

Use your browser’s print dialog and choose “Save as PDF”. This block is hidden when printed.